An article in the August, 2017 issue of The Chronicle of Skin & Allergy (New therapies offer options for patients with IH, page 11) incorrectly described two elements of oral propranolol 3.75 mgmL (Hemangiol, Pierre Fabre Dermo-Cosmetique Canada Inc.).

The article should have noted that the branded product Hemangiol became available in the Canadian marketplace in the second quarter of 2017.

Additionally, the syringe provided with Hemangiol is calibrated in millilitres, not milligrams as indicated in the report.

10 views0 comments

Recent Posts

See All

Role of IL-33 in skin cancer clarified

Researchers have developed a greater understanding of the role interleukin (IL)-33 plays in driving the chronic inflammation that can promote skin and other cancers. This discovery has revealed potent

More Publications by © Chronicle Companies

SkinDaily, Pediatric Chronicle, The Chronicle of Neurology + Psychiatry, Canadian Journal of Medical Cannabis

  • Twitter - Black Circle
  • Facebook - Black Circle
  • YouTube - Black Circle

© Chronicle Companies 2020